In vitro metabolomic analysis demonstrates altered organic acid profiles in pancreatic cancer cells, highlighting potential metabolic biomarkers.
Key Points
Phenylenediamine derivatization achieves recovery rates between 90% and 105% for carboxylic acid-containing metabolites, with detection limits down to 0.01 ng/mL.
Targeted metabolomics with multiple-reaction monitoring LC–MS resolved chromatography issues across diverse organic acids, spanning 0.1 ng/mL to 10 µg/mL linear ranges.
Profiling reveals metabolic perturbations in pancreatic cancer cells compared to normal controls, though clinical validation beyond in vitro cell models is necessary.